HAMP and Iron deficiency anemia: In this 24-week clinical study of PD patients, roxadustat significantly reduced the rise of sTFR and reduced the occurrence of functional iron deficiency by lowering hepcidin levels, although there was no significant difference in the incidence of absolute iron deficiency between the two groups.